Epigenovo, a Uppsala University spinout, is commercializing scFFPE‑ATAC — a single‑cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) samples. The startup published proof‑of‑concept in Nature Communications and is raising funds to kit and offer the assay as a service. Epigenovo’s CEO Camilla Huse Bondesson highlighted that FFPE compatibility is a translational bottleneck for epigenetics; the company’s FFPE‑Tn5 indexing and combinatorial barcoding aim to unlock archived clinical tissue for high‑throughput single‑cell epigenomics.